AGC Biologics Expands Capacity at Denmark Facility
The company is increasing manufacturing capacity at its Copenhagen, Denmark facility with the addition of six new bioreactors.
AGC Biologics, a contract development and manufacturing organization specializing in the clinical and commercial manufacture of therapeutic proteins, announced on Aug. 22, 2018 that the company is increasing manufacturing capacity at its Copenhagen, Denmark facility as part of its global expansion strategy.
The Copenhagen facility will add a single-use bioreactor 6Pack suite consisting of six 2000-L production bioreactors and a 2000-L seed train. The six bioreactors will be run in single unit operations or in groups-simultaneously, sequentially, or staggered-to meet each client's specific production needs. According to the company, the addition of this proprietary bioreactor configuration will enable more flexible, innovative, and customized cGMP production capabilities, offering scales from 2000 L to 12000 L within a single run.
The expansion also includes additional capabilities for harvesting, purification, buffer, and media production that will support the processing of different therapeutic proteins, including high antibody titer processes. The company reports that the new suites are scheduled to be online in November 2018 and are expected to support the manufacturing of several commercial products.
Source: AGC Biologics
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
